LIDDS Inkomsten in het verleden
Verleden criteriumcontroles 0/6
LIDDS's earnings have been declining at an average annual rate of -4.3%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 14.4% per year.
Belangrijke informatie
-4.3%
Groei van de winst
14.4%
Groei van de winst per aandeel
Biotechs Groei van de industrie | 0.7% |
Inkomstengroei | -14.4% |
Rendement op eigen vermogen | -331.6% |
Nettomarge | -150,588.2% |
Volgende winstupdate | 21 Nov 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation
May 26Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation
Dec 15Will LIDDS (STO:LIDDS) Spend Its Cash Wisely?
Jul 19Here's Why We're Not Too Worried About LIDDS' (STO:LIDDS) Cash Burn Situation
Mar 08We're Not Very Worried About LIDDS' (STO:LIDDS) Cash Burn Rate
Nov 23Opbrengsten en kosten
Hoe LIDDS geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 0 | -26 | 5 | 0 |
31 Mar 24 | 0 | -31 | 8 | 0 |
31 Dec 23 | 0 | -40 | 11 | 0 |
30 Sep 23 | 0 | -31 | 14 | 0 |
30 Jun 23 | 1 | -34 | 16 | 0 |
31 Mar 23 | 1 | -37 | 16 | 0 |
31 Dec 22 | 2 | -37 | 16 | 0 |
30 Sep 22 | 4 | -37 | 15 | 0 |
30 Jun 22 | 4 | -36 | 14 | 0 |
31 Mar 22 | 4 | -36 | 13 | 0 |
31 Dec 21 | 4 | -37 | 11 | 0 |
30 Sep 21 | 2 | -41 | 10 | 0 |
30 Jun 21 | 1 | -40 | 10 | 0 |
31 Mar 21 | 1 | -35 | 8 | 0 |
31 Dec 20 | 0 | -32 | 7 | 0 |
30 Sep 20 | 0 | -28 | -12 | 0 |
30 Jun 20 | 0 | -29 | -6 | 0 |
31 Mar 20 | 0 | -32 | 1 | 0 |
31 Dec 19 | 0 | -31 | 7 | 0 |
30 Sep 19 | 0 | -28 | 24 | 0 |
30 Jun 19 | 8 | -15 | 14 | 0 |
31 Mar 19 | 8 | -9 | 8 | 0 |
31 Dec 18 | 9 | -21 | 4 | 0 |
30 Sep 18 | 8 | -1 | 1 | 0 |
30 Jun 18 | 1 | -8 | 6 | 0 |
31 Mar 18 | 1 | -7 | 3 | 0 |
31 Dec 17 | 1 | -7 | 3 | 0 |
30 Sep 17 | 1 | -7 | 3 | 0 |
30 Jun 17 | 0 | -7 | 1 | 0 |
31 Mar 17 | 0 | -7 | 3 | 0 |
31 Dec 16 | 0 | -7 | 3 | 0 |
30 Sep 16 | 0 | -6 | 6 | 0 |
30 Jun 16 | 0 | -6 | 6 | 0 |
31 Mar 16 | 0 | -7 | 7 | 0 |
31 Dec 15 | 0 | -8 | 8 | 0 |
30 Sep 15 | 0 | -8 | 8 | 0 |
30 Jun 15 | 0 | -8 | 8 | 0 |
31 Mar 15 | 0 | -8 | 8 | 0 |
31 Dec 14 | 0 | -7 | 7 | 0 |
30 Sep 14 | 0 | -6 | 6 | 0 |
30 Jun 14 | 0 | -6 | 6 | 0 |
31 Mar 14 | 0 | -4 | 4 | 0 |
31 Dec 13 | 0 | -4 | 4 | 0 |
Kwaliteitswinsten: LIDDS is currently unprofitable.
Groeiende winstmarge: LIDDS is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: LIDDS is unprofitable, and losses have increased over the past 5 years at a rate of 4.3% per year.
Versnelling van de groei: Unable to compare LIDDS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: LIDDS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
Rendement op eigen vermogen
Hoge ROE: LIDDS has a negative Return on Equity (-331.56%), as it is currently unprofitable.